Physician profile
John H Cleator
NPI 1649327446
$5,316.27
in general payments reported to CMS, 2019-2025
33 companies · $805 in 2025
The $805 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $107 · 2020: $620 · 2021: $1,283 · 2022: $898 · 2023: $1,117 · 2024: $486 · 2025: $805.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,408.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,407.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $971.41 | 2019-2024 | Xarelto |
| Pfizer INC. | $798.33 | 2020-2025 | |
| Abbott Laboratories | $581.57 | 2021-2023 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems, Mitraclip |
| Amgen INC. | $527.56 | 2019-2025 | Repatha |
| Novartis Pharmaceuticals Corporation | $320.41 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $285.82 | 2020-2025 | Camzyos, Eliquis |
| Philips North America LLC | $195.29 | 2022-2025 | Ecc Solutions, Mcot, (Ck4) Mcot |
| Actelion Pharmaceuticals US, INC. | $180.46 | 2021-2023 | Uptravi, Opsumit |
| Astellas Pharma US INC | $160.79 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $150.16 | 2022-2025 | Verquvo |
| Sanofi-Aventis U.S. LLC | $112.44 | 2019-2024 | |
| Esperion Therapeutics, INC. | $109.29 | 2020-2021 | |
| Cmp Pharma, INC. | $101.22 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.87 | 2022-2025 | Jardiance |
| Kiniksa Pharmaceuticals International, Plc | $95.91 | 2024 | Arcalyst |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $69.83 | 2020-2022 | |
| Boston Scientific Corporation | $61.57 | 2025 | Cds - Mct/Cem Monitoring, Avvigo Guidance System, Watchman Flx |
| Shockwave Medical, INC | $56.98 | 2021-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $54.77 | 2020-2025 | Lifevest |
| Daiichi Sankyo INC. | $52.88 | 2024-2025 | Injectafer |
| Vital Connect, INC | $48.92 | 2023-2024 | Vitalpatch Rtm |
| Teleflex LLC | $47.06 | 2022-2023 | Vascband |
| B. Braun Interventional Systems INC. | $28.03 | 2022 | |
| Heartflow, INC. | $24.50 | 2023 | Ffrct |
| Novo Nordisk INC | $24.04 | 2025 | Wegovy |
| Cvrx, INC. | $23.55 | 2023 | Barostim Neo System |
| Bayer Healthcare Pharmaceuticals INC. | $21.94 | 2025 | |
| Impulse Dynamics (USA) INC. | $21.83 | 2021 | |
| Alnylam Pharmaceuticals INC. | $21.80 | 2025 | Onpattro |
| Angiodynamics, INC. | $21.17 | 2022 | |
| Elutia, INC. | $20.35 | 2022 | |
| Scpharmaceuticals INC. | $15.26 | 2023 | |
| Baxter Healthcare | $14.26 | 2025 | Hillrom - Carnation Ambulatory Monitor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Cleator listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.